PL2181988T3 - Kompozycje farmaceutyczne oparte na Krystalicznej Postaci I 5-azacytydyny - Google Patents

Kompozycje farmaceutyczne oparte na Krystalicznej Postaci I 5-azacytydyny

Info

Publication number: PL2181988T3
Authority: PL; Poland
Prior art keywords: azacytidine; pharmaceutical compositions; crystalline form; compositions based; crystalline
Prior art date: 2003-03-17

Application number

PL10151392.7T

Other languages

English (en)

Inventor

Dumitru Ionescu

Peter Blumbergs

Lee Alani Selvey

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-17

Filing date

2004-03-16

Publication date

2016-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2181988(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-16 Application filed filed Critical

2016-11-30 Publication of PL2181988T3 publication Critical patent/PL2181988T3/pl

Links

NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 title 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 title 1
229960002756 azacitidine Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

PL10151392.7T 2003-03-17 2004-03-16 Kompozycje farmaceutyczne oparte na Krystalicznej Postaci I 5-azacytydyny PL2181988T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/390,530 US6943249B2 (en)	2003-03-17	2003-03-17	Methods for isolating crystalline Form I of 5-azacytidine

Publications (1)

Publication Number	Publication Date
PL2181988T3 true PL2181988T3 (pl)	2016-11-30

Family

ID=32987551

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04721078T PL1608634T3 (pl)	2003-03-17	2004-03-16	Sposób wyodrębniania krystalicznej formy i 5-azacytydyny
PL10151392.7T PL2181988T3 (pl)	2003-03-17	2004-03-16	Kompozycje farmaceutyczne oparte na Krystalicznej Postaci I 5-azacytydyny

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04721078T PL1608634T3 (pl)	2003-03-17	2004-03-16	Sposób wyodrębniania krystalicznej formy i 5-azacytydyny

Country Status (16)

Country	Link
US (5)	US6943249B2 (pl)
EP (3)	EP1608634B1 (pl)
JP (1)	JP4792550B2 (pl)
AU (2)	AU2004222274B2 (pl)
BR (1)	BRPI0408506A (pl)
CA (1)	CA2518973A1 (pl)
CY (2)	CY1114213T1 (pl)
DK (2)	DK2181988T3 (pl)
EC (1)	ECSP056023A (pl)
ES (2)	ES2575535T3 (pl)
HU (1)	HUE028268T2 (pl)
MX (1)	MXPA05009969A (pl)
PL (2)	PL1608634T3 (pl)
PT (2)	PT1608634E (pl)
SI (2)	SI1608634T1 (pl)
WO (1)	WO2004082822A2 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8902490A (nl) *	1989-10-06	1991-05-01	Leonardus Mathijs Marie Nevels	Werkwijze voor het reinigen van rookgassen.
EP1300992B1 (en) *	2001-10-08	2005-12-28	Alcatel	Method for distributing load over multiple shared resources in a communication network and network applying such a method
US8404716B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7038038B2 (en) *	2003-03-17	2006-05-02	Pharmion Corporation	Synthesis of 5-azacytidine
US6887855B2 (en) *	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US6943249B2 (en)	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US7192781B2 (en) *	2004-04-13	2007-03-20	Pharmion Corporation	Methods for stabilizing 5-azacytidine in plasma
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
EP2073807A1 (en)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008088779A2 (en) *	2007-01-11	2008-07-24	Ivax Pharmaceuticals S.R.O.	Solid state forms of 5-azacytidine and processes for preparation thereof
US20110288042A1 (en) *	2007-08-02	2011-11-24	Chemagis Ltd.	Stable highly pure azacitidine and preparation methods therefor
WO2009042767A1 (en) *	2007-09-26	2009-04-02	Mount Sinai School Of Medicine	Azacytidine analogues and uses thereof
EP2211870A1 (en) *	2007-11-01	2010-08-04	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
PL3692983T3 (pl) *	2008-05-15	2021-12-27	Celgene Corporation	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en)	2008-08-01	2010-02-04	Dr. Reddy's Laboratories Ltd.	Azacitidine process and polymorphs
JP5650643B2 (ja) *	2008-08-08	2015-01-07	サイノファームタイワンリミテッド	５−アザシトシンヌクレオシド及びその誘導体の製造方法
EP2424845A4 (en) *	2009-04-27	2014-03-05	Reddys Lab Ltd Dr	PREPARATION OF DECITABIN
US20110042247A1 (en) *	2009-06-25	2011-02-24	Chandrasekhar Kocherlakota	Formulations of azacitidine and its derivatives
JP2014503597A (ja)	2011-01-31	2014-02-13	セルジーンコーポレイション	シチジンアナログの医薬組成物及びその使用方法
CN103619864A (zh) *	2011-03-31	2014-03-05	细胞基因国际有限公司	5-氮杂胞苷的合成
WO2013022872A1 (en)	2011-08-10	2013-02-14	Celgene Corporation	Gene methylation biomarkers and methods of use thereof
CA2849708A1 (en)	2011-09-23	2013-03-28	Celgene Corporation	Romidepsin and 5 - azacitidine for use in treating lymphoma
CA2849903A1 (en)	2011-09-26	2013-04-04	Celgene Corporation	Combination therapy for chemoresistant cancers
KR101987861B1 (ko)	2011-11-03	2019-06-11	밀레니엄 파머슈티컬스 인코퍼레이티드	Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
WO2013080221A2 (en) *	2011-12-01	2013-06-06	Hetero Research Foundation	Process for alvimopan
US9669048B2 (en) *	2012-10-25	2017-06-06	Fresenius Kabi Oncology Limited	Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
WO2014076616A2 (en) *	2012-11-19	2014-05-22	Shilpa Medicare Limited	Formulations of 5-azacytidine
US9765108B2 (en)	2012-11-19	2017-09-19	Shilpa Medicare Limited	Formulation of 5-azacytidine
WO2014160698A1 (en)	2013-03-26	2014-10-02	Celgene Corporation	SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN103450303A (zh) *	2013-09-04	2013-12-18	重庆泰濠制药有限公司	阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US20160095925A1 (en) *	2014-10-01	2016-04-07	Cadila Healthcare Limited	Stable formulation of azacitidine or salts thereof and their process for preparation
US10695352B2 (en)	2015-10-15	2020-06-30	Celgene Corporation	Combination therapy for treating malignancies
KR102699521B1 (ko)	2015-10-15	2024-08-26	르 라보레또레 쎄르비에르	악성 종양의 치료를 위한 조합물 요법
EP3527226A4 (en) *	2016-10-17	2020-06-17	Daiichi Sankyo Company, Limited	COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
CN109988207B (zh) *	2017-12-29	2022-01-04	江苏豪森药业集团有限公司	阿扎胞苷晶型的制备方法
US10632211B2 (en)	2018-06-11	2020-04-28	The Regents Of The University Of California	Demethylation to treat eye disease
CN110642901A (zh) *	2019-11-11	2020-01-03	扬子江药业集团有限公司	阿扎胞苷甲醇化物及其制备方法和药物组合物、用途
US20240262857A1 (en) *	2021-05-27	2024-08-08	Emory University	Novel universal anti-rna virus agents
WO2026068588A1 (en)	2024-09-30	2026-04-02	Synthon B.V.	Improved azacitidine composition

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1050899A (pl) *	1963-12-22
CH527207A (de)	1968-05-08	1972-08-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) *	1968-11-12	1971-05-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de)	1970-03-14	1981-04-02	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en)	1971-01-26	1972-09-15	Ceskoslovenska Akademie Ved	Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) *	1971-05-04	1982-06-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) *	1975-02-24	1976-09-02	Schering Ag	Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) *	1977-12-20	1979-06-21	Schering Ag	Neues verfahren zur herstellung von nucleosiden
US5700640A (en)	1994-09-16	1997-12-23	Basf Aktiengesellschaft	Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en)	1994-10-17	1996-07-23	Trojan Technologies Inc.	Method of cleaning fouling materials from a radiation module
JPH1053576A (ja) *	1996-06-07	1998-02-24	Eisai Co Ltd	塩酸ドネペジルの多形結晶およびその製造法
TW513409B (en)	1996-06-07	2002-12-11	Eisai Co Ltd	Polymorphs of donepezil hydrochloride
ATE238328T1 (de)	1996-10-16	2003-05-15	Ribapharm Inc	Monozyklische l-nukleoside, analoga und ihre anwendungen
WO2000075143A1 (en) *	1999-06-03	2000-12-14	Eisai Co., Ltd.	Crystals of carbapenem derivatives and pharmaceutical preparations for injection
CA2374737C (en)	1999-07-09	2008-02-12	Boehringer Ingelheim Pharmaceuticals, Inc.	Novel process for synthesis of heteroaryl-substituted urea compounds
EP1248869A2 (en)	2000-01-07	2002-10-16	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
WO2002020453A1 (en)	2000-09-07	2002-03-14	Kaneka Corporation	Methods for crystallization of hydroxycarboxylic acids
CN102942563A (zh) *	2001-03-01	2013-02-27	基利得科学公司	顺-ftc的多晶型物及其它晶型
CA2499036A1 (en)	2002-09-24	2004-04-08	Koronis Pharmaceuticals, Incorporated	1,3,5-triazines for treatment of viral diseases
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040162263A1 (en)	2002-10-31	2004-08-19	Supergen, Inc., A Delaware Corporation	Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
CN1802352A (zh)	2003-02-03	2006-07-12	特瓦制药工业有限公司	制备左乙拉西坦的方法
US6943249B2 (en) *	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en)	2003-03-17	2006-05-02	Pharmion Corporation	Synthesis of 5-azacytidine
US6887855B2 (en) *	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US6877855B2 (en)	2003-07-08	2005-04-12	Dave Ng	Spectacles with peripheral lens support
CN102349927A (zh)	2003-08-29	2012-02-15	Hdac默克研究有限责任公司	联合治疗癌症的方法
US7192781B2 (en)	2004-04-13	2007-03-20	Pharmion Corporation	Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en)	2004-09-17	2006-03-23	Supergen, Inc.	Salts of 5-azacytidine
US20060069060A1 (en)	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
US20060128654A1 (en)	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of cytidine analogs and derivatives
US20080057086A1 (en)	2006-09-01	2008-03-06	Pharmion Corporation	Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en)	2007-01-11	2008-07-24	Ivax Pharmaceuticals S.R.O.	Solid state forms of 5-azacytidine and processes for preparation thereof
US20080182806A1 (en)	2007-01-25	2008-07-31	Nevada Cancer Institute	Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
US20110288042A1 (en)	2007-08-02	2011-11-24	Chemagis Ltd.	Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (en)	2007-10-10	2009-04-15	Cilag AG	Method for producing nucleosides by direct glycosylation of the nucleoside base
EP2211870A1 (en)	2007-11-01	2010-08-04	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
PL3692983T3 (pl)	2008-05-15	2021-12-27	Celgene Corporation	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en)	2008-08-01	2010-02-04	Dr. Reddy's Laboratories Ltd.	Azacitidine process and polymorphs
EP2520581A1 (en)	2008-08-06	2012-11-07	Sicor, Inc.	Method for the determination the purity of 5-Azacytidine
JP5650643B2 (ja)	2008-08-08	2015-01-07	サイノファームタイワンリミテッド	５−アザシトシンヌクレオシド及びその誘導体の製造方法
US20110042247A1 (en)	2009-06-25	2011-02-24	Chandrasekhar Kocherlakota	Formulations of azacitidine and its derivatives
WO2011014541A1 (en)	2009-07-30	2011-02-03	Eagle Pharmaceuticals, Inc.	Stable formulations of azacitidine
IT1399195B1 (it)	2010-03-30	2013-04-11	Chemi Spa	Processo per la sintesi di azacitidina e decitabina

2003
- 2003-03-17 US US10/390,530 patent/US6943249B2/en not_active Expired - Lifetime
2004
- 2004-03-16 WO PCT/US2004/007896 patent/WO2004082822A2/en not_active Ceased
- 2004-03-16 ES ES10151392.7T patent/ES2575535T3/es not_active Expired - Lifetime
- 2004-03-16 DK DK10151392.7T patent/DK2181988T3/en active
- 2004-03-16 PL PL04721078T patent/PL1608634T3/pl unknown
- 2004-03-16 PT PT47210786T patent/PT1608634E/pt unknown
- 2004-03-16 BR BRPI0408506-0A patent/BRPI0408506A/pt not_active IP Right Cessation
- 2004-03-16 EP EP04721078.6A patent/EP1608634B1/en not_active Expired - Lifetime
- 2004-03-16 PT PT101513927T patent/PT2181988E/pt unknown
- 2004-03-16 PL PL10151392.7T patent/PL2181988T3/pl unknown
- 2004-03-16 EP EP10178178A patent/EP2266965A1/en not_active Withdrawn
- 2004-03-16 JP JP2006507211A patent/JP4792550B2/ja not_active Expired - Lifetime
- 2004-03-16 MX MXPA05009969A patent/MXPA05009969A/es active IP Right Grant
- 2004-03-16 EP EP10151392.7A patent/EP2181988B1/en not_active Revoked
- 2004-03-16 DK DK04721078.6T patent/DK1608634T3/da active
- 2004-03-16 AU AU2004222274A patent/AU2004222274B2/en not_active Expired
- 2004-03-16 CA CA002518973A patent/CA2518973A1/en not_active Withdrawn
- 2004-03-16 HU HUE10151392A patent/HUE028268T2/en unknown
- 2004-03-16 ES ES04721078T patent/ES2425474T3/es not_active Expired - Lifetime
- 2004-03-16 SI SI200432065T patent/SI1608634T1/sl unknown
- 2004-03-16 SI SI200432323A patent/SI2181988T1/sl unknown
2005
- 2005-08-05 US US11/198,550 patent/US7700770B2/en not_active Expired - Lifetime
- 2005-09-16 EC EC2005006023A patent/ECSP056023A/es unknown
2010
- 2010-03-22 US US12/729,116 patent/US8211862B2/en not_active Expired - Fee Related
- 2010-11-03 AU AU2010241198A patent/AU2010241198B2/en not_active Expired
2012
- 2012-06-05 US US13/489,307 patent/US8481715B2/en not_active Expired - Fee Related
2013
- 2013-06-07 US US13/913,163 patent/US8975392B2/en not_active Expired - Lifetime
- 2013-08-14 CY CY20131100700T patent/CY1114213T1/el unknown
2016
- 2016-05-31 CY CY20161100474T patent/CY1117639T1/el unknown

Also Published As

Publication number	Publication date
WO2004082822A2 (en)	2004-09-30
PL1608634T3 (pl)	2013-10-31
MXPA05009969A (es)	2006-02-17
EP1608634A2 (en)	2005-12-28
DK2181988T3 (en)	2016-06-06
EP2181988A1 (en)	2010-05-05
HUE028268T2 (en)	2016-12-28
US20130274459A1 (en)	2013-10-17
DK1608634T3 (da)	2013-08-12
JP2006523210A (ja)	2006-10-12
US20120245342A1 (en)	2012-09-27
AU2010241198B2 (en)	2012-05-10
SI1608634T1 (sl)	2013-09-30
AU2004222274B2 (en)	2010-11-04
US7700770B2 (en)	2010-04-20
US8975392B2 (en)	2015-03-10
US8211862B2 (en)	2012-07-03
EP2181988B1 (en)	2016-05-11
CY1114213T1 (el)	2016-08-31
CY1117639T1 (el)	2017-04-26
EP1608634B1 (en)	2013-05-22
PT1608634E (pt)	2013-08-27
US20100292180A1 (en)	2010-11-18
US20040186284A1 (en)	2004-09-23
AU2010241198A1 (en)	2010-11-25
US6943249B2 (en)	2005-09-13
BRPI0408506A (pt)	2006-03-14
ECSP056023A (es)	2006-01-27
AU2004222274A1 (en)	2004-09-30
WO2004082822A3 (en)	2005-07-07
EP1608634A4 (en)	2006-03-15
PT2181988E (pt)	2016-06-15
ES2425474T3 (es)	2013-10-15
CA2518973A1 (en)	2004-09-30
EP2266965A1 (en)	2010-12-29
ES2575535T3 (es)	2016-06-29
US8481715B2 (en)	2013-07-09
US20050272675A1 (en)	2005-12-08
SI2181988T1 (sl)	2016-09-30
JP4792550B2 (ja)	2011-10-12

Publication	Publication Date	Title
SI2181988T1 (sl)	2016-09-30	Farmacevtski sestavki, na osnovi kristalinične oblike I 5-azacitidina
GB2389530B (en)	2007-01-10	Pharmaceutical compositions
GB0321607D0 (en)	2003-10-15	Manufacture of pharmaceutical compositions
GB0320382D0 (en)	2003-10-01	Pharmaceutical compositions
GB0327723D0 (en)	2003-12-31	Pharmaceutical compositions
PT1610784T (pt)	2016-09-23	Formas de 5-azacitidina
SI1575618T1 (sl)	2006-12-31	Disperzijski farmacevtski sestavki
IL173930A0 (en)	2006-07-05	Pharmaceutical compositions containing forms of r-baclofen
GB2391473B (en)	2004-07-07	Pharmaceutical compositions
GB0300531D0 (en)	2003-02-12	Pharmaceutical compositions
EP1648411A4 (en)	2010-03-10	PHARMACEUTICAL COMPOSITIONS
HU0302441D0 (en)	2003-09-29	Pharmaceutical compositions having antibiothic effect
ZA200605080B (en)	2008-06-25	Pharmaceutical compositions
GB0229258D0 (en)	2003-01-22	Medicinal compositions
GB0213481D0 (en)	2002-07-24	Pharmaceutical compositions
EP1655029A4 (en)	2010-01-13	MEDICINAL COMPOSITIONS
AU2003279392A1 (en)	2004-01-06	Pharmaceutical compositions of azithromycin
EP1480649A4 (en)	2006-04-26	STABLE PHARMACEUTICAL COMPOSITIONS
EP1585530A4 (en)	2009-09-09	BIOADHESIVE PHARMACEUTICAL COMPOSITIONS
GB0305579D0 (en)	2003-04-16	Pharmaceutical compositions
PL370907A1 (pl)	2005-05-30	Kompozycje farmaceutyczne
IL173743A0 (en)	2006-07-05	Oral itrazole compositions
GB0218994D0 (en)	2002-09-25	Oral pharmaceutical compositions
GB0221068D0 (en)	2002-10-23	Pharmaceutical compositions
GB0225880D0 (en)	2002-12-11	Pharmaceutical compositions